European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis
Introduction
Worldwide, it is estimated about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018 the predicted annual totals were cervix uteri 569,847, corpus uteri 382,069, ovary 295,414, vulva 44,235 and vagina 17,600 [1].
Depending on tumor type and stage, treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45, early menopause, which increases the risk not only of osteoporosis but also of cardiovascular disease and cognitive decline [2,3]. Surgically induced menopause often leads to the immediate onset of vasomotor symptoms, which may be more severe than after natural menopause [4]. Vasomotor symptoms may last for many years after natural or surgical menopause [[5], [6], [7]]. Other symptoms, such as those related to vulvovaginal atrophy, are lifelong [8,9].
The management of menopausal symptoms in gynecological cancer survivors depends on their age, tumor type and stage, as well as the use of anti-estrogen therapies (for cancers considered to be hormone dependent) and concomitant morbidities. The aim of this position statement is to provide an individualized approach to the management of menopausal symptoms and the prevention and treatment of osteoporosis [10].
Section snippets
Hormonal and non-hormonal management strategies
In women without cancer, administration of systemic estrogen-based menopausal hormone therapy for menopausal symptoms and osteoporosis has a favorable risk–benefit profile for those under the age of 60 years or up to 10 years after menopause [8,[11], [12], [13], [14]]. Systemic menopausal hormone therapy can be administered orally or transdermally. Estrogen alone is given to women who have undergone hysterectomy. Progestogens and the selective estrogen receptor modulator bazedoxifene are added
Endometrial cancer
While most cases of endometrial cancer are diagnosed after the menopause it can occur in younger women, such as those with Lynch syndrome or polycystic ovary syndrome or who are obese. The majority of endometrial cancers are diagnosed at an early stage (Federation of Gynecology and Obstetrics (FIGO) stage I–II) and so have a good overall prognosis, with a 5-year survival rate of over 85 %. Treatment usually involves hysterectomy and bilateral oophorectomy. Studies of menopausal hormone therapy
Conclusion
An individualized approach to the management of menopausal symptoms and prevention and treatment of osteoporosis after gynecological cancer is required. It should take into account age, tumor type and stage, and concomitant therapies and morbidities. It is best undertaken by a multidisciplinary team of health and allied health professionals. It is of concern that there is a paucity of data. Therefore, there is a need for randomized trials and analysis of data registries to provide a stronger
Contributors
Margaret Rees prepared the initial draft, which was circulated to all other named authors for comments and approval before review and endorsement by the EMAS board and IGCS council members. Production was coordinated by Margaret Rees.
Conflict of interest
Margaret Rees reports personal fees from Sojournix, Inc, outside the remit of the submitted work.
Roberto Angioli declares he has no conflict of interest.
Robert L. Coleman reports grants from NIH, grants from Gateway Foundation, grants from VFounation, during the conduct of the study; grants and personal fees from AstraZeneca, grants from Merck, personal fees from Tesaro, personal fees from Medivation, grants and personal fees from Clovis, personal fees from Gamamab, grants and personal fees
Funding
No funding was sought or secured for this position statement.
Provenance and peer review
This is an EMAS and IGCS position statement and was not externally peer reviewed.
Co publication statement
This statement is being simultaneously published in Maturitas and the International Journal of Gynecological Cancer on behalf of the European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS}.
Acknowledgement
The authors thank the board and council members from both societies for their helpful comments.
References (70)
- et al.
Premature menopause or early menopause: long-term health consequences
Maturitas
(2010) - et al.
Surgical menopause
Endocrinol. Metab. Clin. North Am.
(2015) - et al.
Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy
Maturitas
(2018) - et al.
Hot flushes and night sweats symptom profiles over a 17-year period in mid-aged women: the role of hysterectomy with ovarian conservation
Maturitas
(2016) - et al.
EVES Study investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women
Maturitas
(2019) - et al.
Hormone replacement therapy in cancer survivors: utopia?
Crit. Rev. Oncol. Hematol.
(2018) - et al.
Revised global consensus statement on menopausal hormone therapy
Maturitas
(2016) - et al.
Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)
Maturitas
(2016) - et al.
Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation oftolerability and safety
Maturitas
(2019) - et al.
Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase
Maturitas
(2018)